You are here: Home » 2022 » Archives for May 2022

ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Riskified Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RSKD

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Riskified Ltd. (NYSE: RSKD) pursuant and/or traceable to the Registration Statement issued in connection with the Company's initial public offering conducted on or about July 28, 2021 (the "IPO" or "Offering"), of the important July 1, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Riskified securities pursuant and/or traceable to the IPO you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Riskified class action, go to https://rosenlegal.com/submit–form/?case_id=5896 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 1, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO Registration Statement was negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Specifically, the IPO Registration Statement made inaccurate statements of material fact because they failed to disclose the following adverse facts that existed at the time of the IPO: (1) as Riskified expanded its user base, the quality of Riskified's machine learning platform had deteriorated (rather than improved as represented in the Registration Statement), because of, among other things, inaccuracies in the algorithms associated with onboarding new merchants and entering new geographies and industries; (2) Riskified had expanded its customer base into industries with relatively high rates of fraud "" including partnerships with cryptocurrency and remittance business "" in which Riskified had limited experience and that this expansion has negatively impacted the effectiveness of Riskified's machine learning platform; (3) as a result, Riskified was suffering from materially higher chargebacks and cost of revenue and depressed gross profits and gross profit margins during its third fiscal quarter of 2021; and (4) thus, the Registration Statement's representations regarding Riskified's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of Riskified prior to and at the time of the IPO, and were materially false and misleading, and lacked a factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Riskified class action, go to https://rosenlegal.com/submit–form/?case_id=5896 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8540734)

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – LICY, PDAC

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Li–Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. (NYSE: LICY, PDAC) between February 16, 2021 and March 23, 2022, inclusive (the "Class Period"), of the important June 20, 2022 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Li–Cycle securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Li–Cycle class action, go to https://rosenlegal.com/submit–form/?case_id=4885 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 20, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Li–Cycle's largest customer, Traxys North America LLC, is not actually a customer, but merely a broker providing working capital financial to the Company while Traxys tries to sell Li–Cycle's product to end customers; (2) the Company engaged in highly questionable related party transactions; (3) the Company's mark–to–model accounting is vulnerable to abuse and gave a false impression of growth; (4) a significant portion of the Company's reported revenues were derived from simply marking up receivables on products that had not been sold; (5) the Company's gross margins have likely been negative since inception; (6) the Company will require an additional $1 billion of funding to support its planned growth (which is a figure greater than the Company raised via the merger); and (7) as a result, defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Li–Cycle class action, go to https://rosenlegal.com/submit–form/?case_id=4885 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8540777)

ROSEN, A LEADING LAW FIRM, Encourages Natera, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTRA

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Natera, Inc. (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 27, 2022.

SO WHAT: If you purchased Natera securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Natera class action, go to https://rosenlegal.com/submit–form/?case_id=3115 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 27, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Natera class action, go to https://rosenlegal.com/submit–form/?case_id=3115 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8540726)

Lighthouse Labs raises US$7M seed round, co-led by Accel, BlockTower and Animoca Brands, to build the open metaverse navigation engine

MONTREAL, May 11, 2022 (GLOBE NEWSWIRE) — Lighthouse, the company building the open metaverse navigation engine, today announces that it has raised a US$7 million seed round co–led by Accel, BlockTower and Animoca Brands. The round includes participation from White Star Capital, Sparkle Ventures, Gemini Frontier Fund, The Graph core developers StreamingFast, Tiny VC and angels including Patricio Worthalter (founder, POAP), Ryan Selkis (founder, Messari), Alex Svanevik (founder, Nansen), Thibault Launay (founder, Exclusible) and other high profile Web3 investors.

On the back of a year that saw virtual worlds like The Sandbox, Decentraland and Otherside sell hundreds of millions of dollars' worth of land and attract names such as Adidas, Tommy Hilfiger and Snoop Dogg, the metaverse has rapidly captured public interest. Many new worlds have emerged to empower creators and capitalize on a market opportunity estimated at US$680 billion by 2030 (Grand View Research). The ecosystem's rapidly growing level of fragmentation is making discovery an increasingly daunting experience for users and creators, who are now left wondering which world to explore and build experiences into.

Founded by Jonathan Brun and Justine Massicotte, Lighthouse seeks to solve this problem by simplifying discovery and mobility across the spatial web. Its platform, which will launch this summer, will enable users to search for places, events, creators, experiences, and even friends across and within virtual worlds. Beyond search, Lighthouse will offer a portal where users will be able to see trending activities, build groups of friends to explore the metaverse, see where their NFTs are usable and follow the work of specific brands and creators. Prior to launching Lighthouse, Jonathan Brun was Entrepreneur in Residence in White Star Capital's Digital Asset Fund while Justine Massicotte was in charge of the Query Suggest engine at Coveo, a publicly–traded enterprise search company with global operations.

"If you are curious about the metaverse and don't know where to start, Lighthouse will be the place to go," says Jonathan Brun, co–founder and CEO of Lighthouse. "Right now, discovery in the metaverse feels more like gaming, where you need to jump from one game to the next to find things, than the internet, where you can access everything from a single entry point. By building Lighthouse, we take the view that siloed worlds will eventually merge to become closer to the web. We've all seen how much standards and principles of openness propelled our digital lives with the internet. We are confident that Web3 virtual worlds will unite behind our vision of making the open metaverse a searchable place."

“Lighthouse has the exciting opportunity to build a part of the unifying infrastructure for the metaverse,” said Andrei Brasoveanu, Partner at Accel. “The power of the metaverse lies in making it discoverable to a broad range of users, creators, and brands. Jonathan and Justine have thought hard about the opportunity ahead and what it takes to enable everyone to immerse themselves in this increasingly fragmented virtual world. We're looking forward to partnering with the Lighthouse team on this journey!”

To power its platform, Lighthouse partners directly with the worlds for which it provides search capabilities. "Web search engines like Google or Brave use crawlers to discover publicly available web pages. However, because of the heavy and dynamic nature of 3D interactive media, powering real–time search across and within virtual worlds requires direct data integration. The open metaverse is still early, which gives us the opportunity to work hand–in–hand with projects to deploy standards that will ensure that the spatial web forms a cohesive unit," said Lighthouse's co–founder and CTO, Justine Massicotte.

Yat Siu, the executive chairman and co–founder of Animoca Brands, commented: "As a long–time builder and supporter of the open metaverse, Animoca Brands is well aware of Lighthouse's overall value proposition and in particular of the pain points that the company is working to solve. We believe that Jonathan and Justine have the right vision and expertise to execute and we look forward to providing our assistance as they expand the universe of worlds they partner with."

"As users will be spawning with their Avatars identity into many parallel virtual worlds in the open metaverse, we believe a new standard for a navigation system allowing for both content discovery and socialization layers will be needed, to aggregate metadata that facilitates connecting with your friends and communities across them and exploring content from one to another,” said Sebastien Borget, COO & co–founder of The Sandbox. “Lighthouse's vision just focuses on that and we are happy to be working closely with them at The Sandbox and look forward to continuing providing our support to make the future truly open, transparent and interoperable."

The funding will be used to grow Lighthouse's engineering and community teams, expand the universe of worlds it partners with and launch its platform in Summer 2022.

To stay up to date with Lighthouse, keep an eye on their Discord, Medium and follow them on Twitter.

About Lighthouse Labs
Lighthouse is an open metaverse navigation engine that enables the search for places, events, friends, creators, assets, and experiences across and within virtual worlds. Through its portal, Lighthouse empowers users to find trending activities, build groups of friends to explore the metaverse, see where their NFTs are usable and follow the work of specific brands and creators. Lighthouse powers its solution by directly integrating with the virtual worlds for which it provides searchability capabilities. For more information visit: https://www.lighthouselabs.xyz/

Lighthouse is currently looking to expand the universe of worlds it partners with. If you are building a virtual world and would like to collaborate, go to https://www.lighthouselabs.xyz/ to book an intro meeting with the Lighthouse team.

Media Contact
Cat Staffell
[email protected]


GLOBENEWSWIRE (Distribution ID 8540265)

SOLVE FSHD Announces Appointment of Executive Director Dr. Eva Chin and Venture-Philanthropic Funding Structure

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) — Following SOLVE FSHD's recent acclaimed launch, the organization is pleased to formally announce the appointment of Dr. Eva Chin as the Executive Director. SOLVE FSHD's Founder, Chip Wilson, has personally committed USD100 million to find a cure for facioscapulohumeral muscular dystrophy (FSHD), a rare disease he was diagnosed with at the age of 32. As the inaugural Executive Director for SOLVE FSHD, Dr. Chin will be responsible for aligning the organization's goals with the expertise of researchers, scientists and companies to promote and fund the discovery and development of new therapies for FSHD.

"Dr. Chin's experience and specialization in rare neuromuscular diseases add immense value to our organization. We are excited to gain her expertise and guidance to achieve the organization's goal of finding a cure for FSHD by December 2027," says Chip Wilson, SOLVE FSHD Founder. He added, "Within just a few weeks of the organization's launch, SOLVE FSHD has received a tremendous response to the call for qualified grant applications and new therapeutic technologies, which will be reviewed under Dr. Chin's leadership. In addition, she has worked tirelessly to build strong industry alliances for SOLVE FSHD, closely assessed the exciting projects to fund and facilitated collaborative funding opportunities across the academic and industry sectors in FSHD research and drug development."

Dr. Chin obtained her Ph.D. in Physiology from the University of Waterloo in Canada and completed post–doctoral training at the University of Sydney, Australia and U.T. Southwestern Medical Center in Dallas, focusing on intracellular calcium in muscle fatigue and transcriptional regulation of gene expression in muscle fibre type determination and muscle plasticity.

"I am honoured to join the Solve FSHD team, supporting Chip and the Wilson Family in our mission to improve the quality of life for those affected by rare neuromuscular diseases by funding qualified research projects and pre–clinical and clinical research that will accelerate finding a cure for FSHD," says Dr. Eva Chin, Solve FSHD Executive Director.

Dr. Chin's career has spanned the academic and pharmaceutical industries, with previous positions at Pfizer, the University of Maryland, MyoTherapeutics, Cytokinetics and NMD Pharma. While at Pfizer, Eva shifted her career from academic research focusing on cellular and molecular mechanisms of muscle function to discovering and developing muscle–targeted therapies. Over the past five years, she has led the nonclinical development of numerous drug candidates in clinical trials for ALS, SMA, myasthenia gravis and hypertrophic cardiomyopathy.

Under Dr. Chin's guidance, Solve FSHD's venture–philanthropic funding model will strategically utilize Wilson's monetary commitment to support the initial grants, investments in early–stage companies focused on FSHD and to incentivize pharmaceutical companies in the neuromuscular disease space to increase their focus on FSHD. The venture philanthropy model will enable the organization to be financially self–sustainable through return on investments. The investments in viable, albeit high–risk, research opportunities may generate a continued re–investment stream into the organization to further support grant funding initiatives.

"To take advantage of recent advances in genetic therapeutics, SOLVE FSHD constructed a creative funding platform to facilitate the development of treatments that rapidly slow, stop or even reverse weakness in FSHD," said Dr. John Day, MD, Ph.D., Director of Stanford University's Neuromuscular Medicine program. "Having someone with Dr. Eva Chin's experience and capabilities join SOLVE FSHD is critical to establishing the scientifically rigorous program needed to define and validate safe and effective treatments as quickly as possible," says Dr. John Day, MD, Ph.D., Neuromuscular Medicine, Stanford Neuroscience Health Center.

About Solve FSHD
Solve FSHD is funding innovative biotech and biopharma research and development activities that accelerate novel treatments of Facioscapulohumeral muscular dystrophy (FSHD) treatment. It is fully funded and created by Canadian entrepreneur and philanthropist Chip Wilson. The founder of yoga–inspired athletic apparel company Lululemon Athletica inc. has been living with FSHD for the last three decades of his life. He has committed $100 million of his own money to create SOLVE FSHD and kick–start funding into projects that fit the organization's mission: accelerate research into new therapies and find a cure for the disorder by 2027.

Future announcements for grant funding will be issued on SOLVE FSHD's website – https://solvefshd.com/. For early–stage companies, contact SOLVE FSHD at [email protected].

If you have FSHD and want to find out about clinical trials or be included in the FSHD registry, please see SOLVE FSHD's website – https://solvefshd.com/

For media inquiries or to request a media interview, please contact:
Kamran Shaikh, Account Director
PR Associates
[email protected]
778–846–5406

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0e87aacb–92f4–4723–9e7e–e24021cff5f7


GLOBENEWSWIRE (Distribution ID 8540110)

Sphera Tackles Scope 3 Emissions Reporting with Launch of its Automated Life Cycle Assessment Solution

CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) — Sphera , a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services, today announced the launch of its new Life Cycle Assessment (LCA) Automation software, building upon the company's existing LCA solutions. The move comes as investor and regulatory pressures surrounding the standardization and digitalization of end–to–end sustainability data measurement continue to mount, necessitating increasingly sophisticated and granular reporting and compliance tools.

Sphera's next–generation solution integrates seamlessly with customers' existing systems for rapid deployment, allowing customers to quickly receive holistic, real–time analysis and insights into the environmental footprint of their product portfolios. It also features extensive managed content that enables customers to instantaneously calculate their carbon footprint at scale and model how adjustments to specific variables""such as leveraging a cleaner power source or altering production processes""may affect emissions outputs.

The LCA Automation solution serves as an extension of Sphera's existing Product Sustainability capabilities which include life cycle assessment software and content. The service allows a company to increase the number of LCAs by a factor of 1,000, in turn enabling the experienced LCA professional to focus on analyzing and improving results, versus creating them.

The overarching goal of Sphera's LCA Automation tool is to help businesses""especially those in sectors with complex supply chains, such as manufacturing, consumer goods, paints and chemicals""to more effectively reduce their greenhouse gas (GHG) emissions at every step of production, from design to disassembly. Improved forecasting will facilitate holistic corporate decisions with sustainability incorporated at each stage, allowing teams to proactively predict and control environmental impact.

Paul Marushka, Sphera's CEO and president, says: "Historically, LCAs have been viewed as voluntary, ad–hoc add–ons to broader corporate sustainability efforts. However, with consumer awareness growing in–step with regulatory mandates to mitigate the effects of climate change, LCA Automation feeds into the highest needs of decarbonization. As recent moves from the EU, SEC and the latest IPCC report have shown, financial and reputational fallout from a failure to act are very much a "when', not an "if'."

Continues Marushka, "From helping engineers create more sustainable products to enabling procurement professionals to establish lower carbon emission supply chains, LCA Automation will transform decision–making, for the benefit of both businesses and our planet."

About Sphera
Sphera is the leading provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services focusing on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship. For more than 30 years, we have served over 3,000 customers and a million–plus users in 80 countries to help companies keep their people safe, their products sustainable and their operations productive. Learn more about Sphera at www.sphera.com. Follow Sphera on LinkedIn.

Contact Information:
Astrid Dickinson
[email protected]


GLOBENEWSWIRE (Distribution ID 8538320)

RCSI Bahrain continues to meet Global Healthcare Educational Standards and support the development of national healthcare programmes in the Gulf Countries

Bahrain, Manama, May 10, 2022 (GLOBE NEWSWIRE) — In line with the global standards of quality medical education, the Royal College of Surgeons in Ireland "" Medical University of Bahrain (RCSI Bahrain) received re–accreditation from the Medical Council of Ireland (IMC) for its undergraduate medicine programme in 2021, and revalidation from the Bahrain Education & Training Quality Authority (BQA) for its undergraduate nursing and MSc in nursing programmes in 2022. The undergraduate medicine programme has been accredited by the IMC since 2014 and the RCSI Bahrain School of Medicine is included in the World Directory of Medical Schools and listed on the International Association of Universities' "List of Universities of the World" by the UNESCO.

To perform the re–accreditation process, the IMC visiting team chaired by the Medical Council Member, Professor Mary O'Sullivan, Dean of the University of Limerick, Ireland, and comprising of Council and external members, met with the RCSI Bahrain Executive Management Team, School of Medicine staff, the University's Student Council, students from all year groups and RCSI Bahrain interns. This being to carry out the undergraduate medicine programme accreditation in alignment with the World Federation of Medical Education's (WFME) "Global Standards for Quality improvement in Medical Education' framework. The IMC issued a five–year renewal of the accreditation of the undergraduate medicine programme, which is valid until November 2026.

The BQA's review panel led by Professor Erika Sirsch, acting Dean of the nursing science faculty at the Philosophical–Theological University of Vallendar, Germany, comprised of three regional and international healthcare professionals, in addition to the BQA members. The review involved meetings with the RCSI Bahrain Executive Management Team, staff from both the School of Nursing and Midwifery and the School of Postgraduate Studies and Research, staff across the University's support units, as well as students and alumni. RCSI Bahrain received the decision of Full Confidence from the BQA and it continues to maintain its valid status as placed on National Qualifications Framework of Bahrain (NQF) for its Undergraduate Nursing and MSc in Nursing programmes.

Both visits from the IMC and BQA involved several meetings with RCSI Bahrain training leads and Clinical Lecturers and Tutors, programme Advisory Boards and employers from the Ministry of Health and the University's partner hospitals including King Hamad University Hospital, Bahrain Defence Force Hospital "" Royal Medical Services, Salmaniya Medical Complex, American Mission Hospital, multiple health centres across Bahrain and Cleveland Clinic in Abu Dhabi, UAE.

President of RCSI Bahrain, Professor Sameer Otoom commented, "With our accreditation standards and a world–renowned curriculum, RCSI Bahrain graduates attain a level of knowledge and clinical experience to compete for rewarding career opportunities worldwide, as well as supporting the development of national healthcare programmes in the Gulf Countries".

–Ends–

About RCSI Bahrain

RCSI Bahrain is a constituent university of RCSI, which was established in Dublin, Ireland, in 1784. RCSI Bahrain, an independent private university, opened its doors to a cohort of 28 medical students in 2004. It is a not–for–profit health sciences institution focused on education and research to drive positive change in all areas of human health worldwide. Today, the purpose–built campus is home to a student body of more than 1,300 across Schools of Medicine; Nursing and Midwifery and Postgraduate Studies and Research.

For more information, please visit www.rcsi.com/bahrain

RCSI Bahrain Instagram

RCSI Bahrain Facebook

RCSI Bahrain LinkedIn

Attachments


GLOBENEWSWIRE (Distribution ID 8539563)

Reuters Partners with The Globe and Mail’s Sophi.io Automation Platform

TORONTO, May 10, 2022 (GLOBE NEWSWIRE) — Sophi.io, an AI–powered automation, optimization and prediction platform developed by The Globe and Mail, is now working with Reuters – the news and media division of Thomson Reuters – as it continues to invest in the latest AI solutions for its newsroom. Sophi is helping to automate content curation on select sections on Reuters.com, which was relaunched in April 2021.

Sophi Site Automation is an AI system that autonomously curates digital content to find and promote an organization's most engaging content. Sophi looks at all content as it's published, and all traffic, to find the hidden gems that an organization's customers value the most.

In order to automate content curation, Sophi's algorithm has been learning from Reuters editors. The newsroom has been able to work with some of the latest AI solutions, which has resulted in giving time back to editors to focus on finding the next story and creating the journalism that makes Reuters such a trusted brand.

Josh London, Head of Reuters Professional and Chief Marketing Officer of Reuters, said: "Sophi's cutting–edge AI platform is one of the next steps in the evolution of our digital properties. Sophi will help us further our mission of bringing AI–based technology and tools to more corners of the workforce, whilst helping to bring our readers the stories they both want and need to know."

Michael Young, Chief Technology Officer for Reuters, said: "Our partnership with Sophi.io is another example of how a newsroom like ours can successfully deploy some of the latest AI solutions for effective content discovery. Our team worked closely with the Sophi team to ensure our Sophi Score reflected our business goals and we are pleased with the resulting site automation."

Mike O'Neill, Co–Founder and CEO of Sophi.io, added "We are delighted to have Reuters as a customer. They put their trust in Sophi and we are excited to automate curation across all of their article pages to start and expand the relationship to include more solutions down the road."

"It's wonderful to work with Reuters in this capacity," said Phillip Crawley, Publisher and CEO of The Globe and Mail. "They have a strong mission and Sophi.io is helping them continue to demonstrate how editorial integrity can be supported by AI."

About Reuters
Reuters is the world's leading provider of trusted news, insight and analysis, reaching billions of people worldwide every day. Founded in 1851, it brings together world–class journalism, industry expertise and cutting–edge technology with unparalleled speed, reliability and accuracy to enable people to make better decisions. Reuters is committed to the Trust Principles of independence, integrity and freedom from bias, and is the essential source of business, financial and world news delivered to financial professionals exclusively via Refinitiv services, and to the world's media organizations, industry events and directly to consumers.

About Sophi.io
Sophi.io (https://www.sophi.io) was developed by The Globe and Mail to help content publishers make important strategic and tactical decisions. It is a suite of AI and ML–powered automation, optimization and prediction solutions that include Sophi Site Automation, Sophi for Paywalls and Sophi for First Party Data. Sophi also powers one–click automated laydown of template–free print publishing. Sophi is designed to improve the metrics that matter most to your business, such as subscriber retention and acquisition, engagement, recency, frequency and volume.


GLOBENEWSWIRE (Distribution ID 8539467)

Taconic Biosciences Appoints Nomura Siam as Distributor in India for All Taconic Animal Models

RENSSELAER, N.Y., May 10, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, has appointed Nomura Siam International Co., Ltd (NSI), an established distributor of laboratory animals and related products, as its preferred distributor in India.

India makes a significant contribution to global pharmaceutical and vaccine production, and its pharmaceutical and biotechnology research and development is expected to grow over the next decade. To support this growth, scientists in India need advanced mouse and rat models for pharmacology studies and toxicology and drug safety assessment. Research across all therapeutic areas requires genetically engineered models (GEMs). Additionally, mice with humanized immune systems are critical for immuno–oncology and other applications.

Taconic's portfolio comprises nearly 4,700 mouse and rat models, including widely used standard strains, immunodeficient models, and exclusive GEMs. Taconic is also a global leader in humanized immune system mouse generation. Taconic's industry–leading quality systems, genetic integrity, and globally harmonized animal health standards promote research reproducibility while its flexible approach to licensing reduces barriers to accessing valuable GEMs.

Based in Thailand, NSI is known for its focus on quality and customer service. The company's new agreement with Taconic significantly increases preclinical researchers' access to GEMs in India and allows NSI to offer this market a full spectrum of solutions.

"To date, rodent model selection and availability has been somewhat limited in India. We believe this partnership will provide India's growing pharmaceutical industry access to the most sophisticated and high–quality animal models available globally," said Dr. Michael Seiler, vice president of commercial products at Taconic. "We truly believe this partnership will support Taconic's desire to accelerate new life–saving therapeutics for the global community."

"Taconic's portfolio of sophisticated mouse models fills a major gap in the Indian market," said Taiichiro Kamiya, president of NSI. "By our frequent information sharing, and the improvement of logistic process, we will provide faster and easier access to GEMs for Indian users."

To learn more about Taconic's full line of animal model solutions, please call 1–888–TACONIC (888–822–6642) in the US, +45 70 23 04 05 in Europe, or email [email protected].

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom–generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno–oncology mouse models, and integrated model design and breeding services, Taconic operates service laboratories and breeding facilities in the US and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.

About Nomura Siam International Co. Ltd. (NSI)

Nomura Siam International Co. Ltd., based in Bangkok, Thailand, was jointly established in 2012 by CLEA Japan, Inc. and Nomura Jimusho, Inc. as a comprehensive provider for the laboratory animal field. As a one–stop service supplier, NSI not only sells laboratory animals but also handles a wide range of related products, including equipment for breeding, conducting experiments, and environmental enrichment, as well as consulting services for preclinical research and laboratory animal facility design.

Media Contact:

Aidan Bouchelle
Associate Director, Marketing Operations
518–949–7598
[email protected]


GLOBENEWSWIRE (Distribution ID 8537399)

Dante Labs receives grant by Italian government to pilot revolutionary CE-IVD, clinical whole genome sequencing-based Citizen Test for a G7 country, starting a new era in clinical genomics

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully–CE–IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test.

The goal of the project is to introduce clinical whole genome sequencing with clinical reports in the standard medical care of the country's hospitals and healthcare system and is the first step to introduce whole genome sequencing in the national healthcare system of a European and G7 country. The test will leverage Dante's proprietary Extensa software for reporting, interpretation and analysis of whole genome and medical data.

"Clinical whole genome sequencing will finally become a standard solution in public healthcare systems, not as a luxury for the few but as a right for every citizen, thanks to the Dante Citizen Test," said Andrea Riposati, CEO of Dante Labs. "The effective use of whole genome sequencing in standard clinical care requires mastery at sequencing, interpretation and integration of medical information, at scale. This is what we have been doing at Dante. Now, with partnerships with forward looking governments, like Italy's, we can impact millions of patients worldwide."

The groundbreaking project will be overseen by the Dante's newly appointed European Medical Genomics Board, which is made of national and multinational world leaders in genomics, including geneticists, molecular biochemists and clinical experts in pharmacogenomics, nutrigenomics and oncogenomics, prenatal, neonatal and pediatric rare diseases.

About Dante Labs

Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:

Laura D'Angelo
VP of Investor Relations
[email protected]
+39 0862 191 0671
www.dantelabs.com


GLOBENEWSWIRE (Distribution ID 8538985)